Immediate-release tablet manufacture with vibegron is structured around a 75 mg unit dose, which is the reference oral strength; the active pharmaceutical ingredient is the free base, CAS 1190389-15-1, molecular weight 444.53 g/mol. Direct-compression formulation work assigns a total core weight of 250 mg to 500 mg, placing the API addition ratio at 15.0% to 30.0% w/w; at a 300 mg core mass, the nominal load is 25.0% w/w. Exact excipient percentages in the reference film-coated tablet are not disclosed in approved labeling, so these values function as design targets rather than compendial specifications. Incoming API lots are qualified against ICH Q3D(R2) oral elemental impurity permitted daily exposure values, ICH Q3C(R8) residual solvent limits, and ICH Q3A(R2) organic impurity thresholds. Pre-drying at 40°C under vacuum is required when loss on drying exceeds 2.0% w/w, particularly in warehouses with ambient RH above 60%. Direct compression is viable only when the API lot exhibits a particle size d90 below 75 µm, a flow function coefficient above 5.0 measured on a ring shear tester following ASTM D6773-20, and agglomerate height below 5.0% after 15 min in a 10 rpm bin blender. Production-scale rotary tablet presses with precompression stations are operated at precompression force 4–8 kN and main compression force 8–20 kN; tablet hardness is held at 40–70 N. Failure modes observed on commercial lines include edge capping when main compression exceeds 22 kN while lubricant level is below 0.25% w/w, and punch filming when crystalline API fines adhere to tooling at punch-tip temperatures above 35°C.

For API lots that fall outside direct-compression limits, roller compaction or wet granulation is used. Roller-compacted ribbons are targeted to 0.8–1.1 g/cm³ solid fraction, milled through an oscillating granulator with screen aperture 0.8–1.25 mm, and blended with a final lubricant level of 0.5–1.5% w/w magnesium stearate for 3–5 min. High-shear wet granulation uses 100–300 L vertical granulators with impeller tip speed 5–12 m/s and fluid-bed drying inlet temperature 60–70°C until granule moisture reaches 1.5–2.5% w/w. Each granulated lot is compressed to 75 mg strength and tested for uniformity of dosage units according to USP <905> and dissolution according to USP <711> apparatus II at 50 rpm in 900 mL media. Aqueous hypromellose-based film coating is applied at 2–4% w/w weight gain in a side-vented pan at 60–70°C inlet air, 8–10°C dew point, and 45–50°C exhaust temperature; the terminal product is a film-coated immediate-release tablet. Coating pan speed is typically 2–6 rpm with spray rate calibrated to avoid tablet surface override and logo bridging.

What Limits Blend Uniformity and Dissolution After Scale-Up from 30 kg Pilot Batches to 300 kg Production Batches?

The primary scale-up conflict in vibegron tablet blending is mechanical rather than chemical: magnesium stearate added at 0.25% w/w is sufficient to prevent punch sticking at 30 kg, yet at 300 kg batch size the same percentage can remain low for uniform lubrication while mixing beyond 10 min creates hydrophobic films on mannitol and microcrystalline cellulose surfaces. The resulting dissolution slowdown is measured as a drop in percentage released at 15 min in USP <711> apparatus II; when release at 15 min falls below 80% for a reference immediate-release profile, the batch is held pending root-cause evaluation under FDA 21 CFR 211.192. Blending is therefore structured as a two-stage process: API is first pre-dispersed with mannitol in a 1:1 ratio through a 500 µm sieve, then loaded into a 600 L bin blender filled to 60–70% of volumetric capacity and rotated at 8–12 rpm for 15–25 min. Lubricant is added only after blend uniformity testing shows RSD ≤ 5.0% across 10 stratified sampling points. Process validation protocols reference FDA 21 CFR 211.110 for in-process control, ASTM E2709-19 for lot acceptance sampling plans, and USP <905> acceptance value ≤ 15.0 for content uniformity.

The addition ratio is fixed by the cycle: API 75 mg per unit; mannitol from 30% to 60% w/w; microcrystalline cellulose from 20% to 50% w/w; croscarmellose sodium 2–5% w/w; magnesium stearate 0.5–1.5% w/w. Batch records from production-scale lines show that final blend bulk density rises from 0.40 g/mL to 0.55 g/mL during bin blending, and compressing immediately after transfer without a surge hopper can induce segregation of coarse mannitol particles above 180 µm. The resulting commercial presentation remains the film-coated tablet of 75 mg strength, with hardness, friability, disintegration, assay, impurities, content uniformity, and dissolution checked against the approved specification and release limits.

Capsule and unit-dose granule presentations are screened for clinical settings where intact tablet swallowing is contraindicated. The addition ratio is maintained at 75 mg vibegron per capsule or sachet; total fill weight ranges from 200 mg to 400 mg, so the API load spans 18.75–37.5% w/w depending on filler density and powder flow. If the formulation is manufactured as a marketed product, USP <905> and USP <711> apply; if it is prepared extemporaneously for a specific patient, USP <795> nonsterile compounding standards govern beyond-use dating and stability. Dissolution method development follows USP <1092> and includes a media screen because sink conditions in plain aqueous buffers are not guaranteed for this compound; surfactant addition, such as 0.1% sodium dodecyl sulfate, is selected only after pH-solubility profiling justifies it.

Automatic capsule filling on dosing-disc or dosator machines is constrained by powder bed depth and pin compression. Fill weight variation is recorded at 10 min intervals; fill weight RSD above 4.0% triggers machine adjustment under FDA 21 CFR 211.110. For granules, the dry granulation route is preferred over wet massing when the API is moisture-sensitive; the powder is slugged at 8–14 kN on a rotary tablet press, milled through a 1.0 mm screen, and filled into HPMC or pullulan capsule shells or sealed foil sachets. An alternative fluid-bed drug-layering method disperses vibegron on microcrystalline cellulose spheres of 200–400 µm using a polymer binder at 3–6% w/w and a drug-loading target of 5–15% w/w of coated sphere mass. Finished presentations are HPMC capsules of size 1 or 2, and single-dose granule sticks intended for sprinkling on soft food; such oral granules are not automatically interchangeable with the film-coated tablet without bioequivalence data.

When an Injectable Presentation Is Screened, Aseptic Processing and Parenteral Elemental Impurity Limits Replace Oral Formulation Norms

No approved injectable vibegron product exists in the United States, European Union, or Japan at the time of writing, and published data for specific parenteral concentrations are limited. The addition ratio cannot be fixed by a pharmacopoeial monograph, and any claim that a particular mg/mL concentration is validated would be unsupported. Feasibility work for poorly aqueous soluble weak bases therefore begins with pH-solubility profiling across pH 2.0–7.4, with organic co-solvent titration using propylene glycol or polyethylene glycol 300 and cyclodextrin or surfactant screens only after simple pH adjustment proves insufficient. Starting screening concentrations in the range of 0.1–5.0 mg/mL are used as experimental bracketing points, not as validated formula strengths. The sterile dosage form, if advanced, would be governed by USP <1>, USP <71> sterility testing, USP <788> sub-visible particulate matter, USP <790> visible particulates, and ICH Q3D(R2) parenteral permitted daily exposure values, which are more restrictive than oral limits in selected elemental impurity classes.

Sterile filtration and container closure integrity apply as terminal requirements. A 0.22 µm PVDF or PES filter is evaluated for flux decline and adsorption; if API loss exceeds 5.0% after 100 mL/m², a different filter polymer is selected. The dosage form is a lyophilized vial or a terminally sterilized solution only if the API can withstand the selected sterilization cycle; otherwise aseptic processing following EU GMP Annex 1 and ISO 13408-1:2023 is required. Lyophilization feasibility studies include controlled nucleation at −40°C to −45°C shelf temperature, primary drying at −30°C to −10°C, and secondary drying at 25–35°C with chamber pressure 50–150 µbar, but published vibegron-specific cycle data are limited. Terminal dosage forms under investigation are sterile lyophilized vials or sealed aqueous vials of 2 mL to 10 mL, labeled as investigational sterile preparations rather than approved drug products.

Fluid energy milling is applied when the unprocessed vibegron lot gives dissolution release below the intended profile in 0.1 M HCl, pH 4.5 acetate, and pH 6.8 phosphate media using USP <711> apparatus II at 50 rpm. The milling target is a d90 below 20 µm; jet mills operated at 0.6–0.9 MPa grinding gas pressure and 0.7–1.0 kg/h feed rate produce narrow distributions when classifier speed is held constant. However, published data for vibegron-specific milled lots are limited, so the d90 threshold is a process development starting point rather than a compendial requirement. The addition ratio for a co-milled preblend is determined by the carrier chosen; API-to-carrier ratios from 10% to 50% w/w are screened, but no fixed ratio applies across all oral dosage forms.

After milling, the powder is tested for process-induced disorder by X-ray powder diffraction and differential scanning calorimetry; amorphous content above 10% can accelerate recrystallization under storage at 40°C/75% RH, which is evaluated under ICH Q1A(R2). The milled API is then incorporated into direct-compression tablets or capsules at the same 75 mg unit strength. In-process controls include laser diffraction particle size analysis, residual moisture, and impurity assay against ICH Q3B(R2); final dosage forms are film-coated tablets or HPMC capsules meeting USP <905> and USP <711>.